Spectrum pharmaceuticals inc (SPPI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows From Operating Activities:
Cash Flows From Operating Activities:
Loss from continuing operations

-135,386

-126,706

-100,752

-

-

-

-

-

-

-

-

Income from discontinued operations, net of income taxes (Note 10)

22,697

5,965

8,563

-

-

-

-

-

-

-

-

Net loss

-112,689

-120,741

-92,189

-69,770

-52,642

-45,719

-62,134

94,201

49,931

-48,844

-20,192

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred revenue

-

-

-

-

-

-

12,400

12,300

12,300

12,300

9,186

Depreciation and amortization

1,620

28,409

27,972

26,492

31,869

25,352

22,096

12,243

5,650

4,506

4,244

Stock-based compensation (Note 4)

21,838

17,483

15,139

13,670

13,941

11,809

12,423

14,884

22,237

8,285

7,423

Recognized gain on Commercial Product Portfolio Transaction (Note 10)

34,568

0

0

-

-

-

-

-

-

-

-

Amortization of operating leases (Note 10(a))

1,715

0

0

-

-

-

-

-

-

-

-

Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))

431

0

0

-

-

-

-

-

-

-

-

Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))

205

0

9,651

2,217

0

0

-

-

-

-

-

Realized gain on sale of CASI stock (Note 8)

-2,674

0

0

-

-

-

-

-

-

-

-

Unrealized loss (gain) on CASI stock holdings (Note 3(a) and Note 8)

-12,665

10,458

0

-

-

-

-

-

-

-

-

Unrealized gains on marketable securities (Note 3(a))

-

-

-

0

-

-

-

-

-

-

-

Impairment of intangible assets (Note 3(g))

-

-

-

-

7,160

0

1,023

-

-

-

-

Change Of Business Acquisition Contingent Consideration At Fair Value

-

-

-

-649

676

987

2,871

-20

-

-

-

Change in fair value of Allos deferred development costs and deferred payment contingency (Note 16)

-

-

-

-

-

-

-2,869

-

-

-

-

Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 17(b)(x)) and ROLONTIS (Note 17(b)(xiii)) milestone achievements

-

-

-

2,419

0

7,790

0

-

-

-

-

Unrealized loss on CASI stock holdings (Note 3(a) and Note 7)

6

-10

23

-

-

-

-

-

-

-

-

Provision for inventory obsolescence

-

-

-

-

-

-

-

-

-

50

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-132

-38

-11

-

Unrealized gain from transactions denominated in foreign currency

1,469

-31

5,237

153

157

-6,033

-1,222

-107

-

-

-

Change in deferred tax liabilities

1,478

-1,927

4,957

-104

210

-602

0

-

-

-

-

Unrealized loss (gain) on marketable securities (Note 3(a))

-

-

-

0

-

-

-

-

-

-

-

Change in fair value of contingent consideration (Note 8(b))

0

1,931

4,890

-

-

-

-

-

-

-

-

Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 9)

0

220

567

5,710

5,250

4,818

-

-

-

-

-

Bad debt expense (recovery)

-12

12

-17

57

0

-85

127

-128

245

359

-

Fair value of common stock issued for drug license

-

-

-

-

-

-

-

-

-

3,105

935

Change in fair value of common stock warrants issued to non-employees

-

-

-

-

-

-

-356

-

-3,488

2,731

8,075

Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)

-

-

-

-

-

-

43

-

-

-

-

Write off of Deferred Debt Issuance Cost

-

-

-

696

662

599

101

-

-

-

-

Loss on 2018 Convertible Note purchase (Note 9)

0

0

-845

-25

0

0

-

-

-

-

-

Change in cash surrender value of corporate-owned life insurance policy

0

5

418

137

0

0

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

-29,420

-2,844

-7,694

9,494

-40,245

21,671

-42,559

33,504

30,897

12,752

-1,118

Other receivables

5,871

1,571

-3,663

-6,895

7,017

-2,070

0

-

-

-

-

Inventories

2,037

-3,390

-4,318

5,800

-1,863

-4,253

-1,570

-3,530

6,528

1,054

1,389

Prepaid expenses and other assets

2,473

3,642

6,137

423

446

718

359

-9,483

7,115

134

250

Deferred tax assets

-

-

-

-

-

-1,724

-33,252

34,605

-

-

-

Other assets

1,188

-5,010

-1,573

2,043

1,731

13,161

8,989

-

-

-

-

Accounts payable and other accrued liabilities

-35,769

12,112

6,459

-4,033

-28,298

5,304

-23,897

24,038

15,711

21,546

7,097

Accrued payroll and benefits

-2,168

592

280

790

-233

1,594

425

-9,726

-1,525

-47

404

FOLOTYN development liability

-4

-389

-744

-1,556

-1,100

-1,957

-5,917

2,376

3,519

503

1,149

Acquisition-related contingent obligations

-

-

-

-1,300

0

0

-

-

-

-

-

Contract liabilities (Note 3(i))

-4,850

4,850

0

-

-

-

-

-

-

-

-

Other long-term liabilities

3,047

-564

-3,389

2,153

1,355

124

2,153

1,208

834

-

-

Deferred revenue

0

0

593

-2,985

-3,511

9,803

0

-

-

-

-

Landlord contributions to tenant improvements

-

-

-

-

-

-

-

-

-

995

-

Deferred revenue and other credits

-

-

-

-

-

-

-

-

-

15,958

-912

Net cash used in operating activities

-134,631

-62,403

-38,855

-40,459

6,744

-3,627

-2,086

71,959

43,288

-22,544

-17,634

Cash Flows From Investing Activities:
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction (Note 1(b))

158,571

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

77,475

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of CASI stock (Note 8)

5,074

0

0

-

-

-

-

-

-

-

-

Sales and maturities of marketable securities

-

-

-

-

-

-

-

72,463

18,255

32,391

25,783

Purchases of investment securities available-for-sale (Note 3(a))

200,160

0

0

-

-

-

-

26,430

17,027

40,649

-

Purchases of property and equipment (Note 3(b))

9,018

107

465

78

223

934

161

312

475

1,576

673

Proceeds from sale of property and equipment

50

0

0

-

-

-

-

-

-

-

-

Proceeds from redemption of corporate-owned life insurance policy

0

4,130

0

0

-

-

-

-

-

-

-

Payments to Acquire Intangible Assets

0

2,650

0

0

-

-

-

-

-

-

-

Payment for corporate-owned life insurance premiums

0

0

601

601

0

0

-

-

-

-

-

Purchase of equity securities (Note 8)

0

0

15

0

0

-

-

-

-

-

-

Purchases of available-for-sale securities

-

-

-

-

-

-

-

1,712

164

-

-

Proceeds from sale of available-for-sale securities

-

-

-

-

3,061

4,093

0

-

157

-

-

Capitalized cash milestone payment upon FDA approval of BELEODAQ

-

-

-

-

-

25,000

-

-

-

-

-

Acquisition

-

-

-

-

-

-

-

133,264

-

-

30,940

Net cash provided by investing activities

31,992

1,373

-1,081

-679

2,838

-21,841

-14,330

-114,690

746

-9,834

-5,830

Cash Flows From Financing Activities:
Cash Flows From Financing Activities:
Proceeds from Mundipharma related to FOLOTYN collaboration (Note 16)

-

-

-

-

-

-

7,000

-

-

-

-

Proceeds from employees for exercises of stock options

7,147

13,475

5,477

203

1,482

1,906

3,576

5,817

5,137

3,074

1,262

Proceeds from exercise of common stock warrants

-

-

-

-

-

-

-

89

24,808

-

-

Proceeds from sale of stock under our employee stock purchase plan

663

1,122

1,010

668

627

639

495

606

655

-

-

Proceeds from issuance of common stock to employees - shelf takedown

-

-

-

-

-

-

-

-

-

-

1,167

Proceeds from sale of common stock under an at-the-market sales agreement (Note 5)

1,817

0

128,272

73,869

0

0

-

-

-

554

292

Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock

0

4,645

0

0

-

-

-

-

-

-

-

Payments to tax authorities upon employees' surrender of restricted stock upon vesting and upon exercises of stock options

0

27,679

4,331

1,397

-

-

-

-

-

-

-

Payment of principal upon the maturity of the 2018 Convertible Notes (Note 9)

0

20

0

0

-

-

-

-

-

-

-

Proceeds from issuance of common stock from stock option exercises

-

-

-

-

-

-

-

-

-

-

95,810

Repurchase of stock options pursuant to tender offer

-

-

-

-

-

-

-

-

-

-

2,520

Purchase of treasury stock

-

-

-

-

-

-

1,651

9,057

2,926

-

-

Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting

-

-

-

-

638

1,733

1,509

1,434

4,032

-

-

Payment of contingent consideration related to EVOMELA acquisition (Note 10(b))

-

-

-

4,700

0

0

-

-

-

-

-

Purchase of 2018 Convertible Notes (Note 9)

0

0

27,500

9,014

0

0

-

-

-

-

-

Purchase of warrants related to the conversion hedge of 2018 Convertible Notes (Note 9)

0

0

27,189

330

0

0

-

-

-

-

71

Proceeds from sale of call options related to the conversion hedge of 2018 Convertible Notes (Note 9)

0

0

32,982

351

0

0

-

-

-

-

-

Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 7)

-

-

-

6

0

0

-

-

-

-

-

Payment of stock dividend

-

-

-

-

-

-

-

9,011

-

-

-

Repayment of capital leases

-

-

-

-

-

-

-

9

31

29

-

Proceeds from revolving line of credit (Note 14)

-

-

-

-

-

-

100,000

125,000

-

-

-

Repayment of revolving line of credit (Note 14)

-

-

-

-

-

-

175,000

50,000

-

-

-

Proceeds from 2018 Convertible Notes (Note 15)

-

-

-

-

-

-

120,000

-

-

-

-

Deferred financing costs (Note 15)

-

-

-

-

-

-

4,573

-

-

-

-

Proceeds from sale of common stock warrants for 2018 Convertible Notes issuance (Note 15)

-

-

-

-

-

-

12,612

-

-

-

-

Payment of debt issuance costs (Note 13)

-

-

-

-

-

-

-

976

-

-

-

Purchase of common stock call options related to 2018 Convertible Notes issuance (Note 15)

-

-

-

-

-

-

-25,692

-

-

-

-

Net cash provided by financing activities

9,627

-8,457

108,721

59,644

1,471

812

35,258

61,025

23,611

3,599

95,940

Effect of exchange rates on cash and equivalents

-50

-356

316

-25

-1,254

-1,708

-2,235

202

-

-

-

Net increase in cash, cash equivalents and restricted cash

-93,062

-69,843

69,101

18,481

9,799

-26,364

16,608

18,496

67,645

-28,779

72,476

Noncash investing activities:

-

-

-

-

-

-

1,652

11,983

-

-

-

Inventory liability assumed in acquisitions

-

-

-

-

-

-

-

580

-

-

-

Additions of property and equipment that remain in accounts payable and other accrued liabilities (Note 3(b))

2,760

0

0

-

-

-

-

5,000

-

-

-

Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases

1,835

0

0

-

-

-

-

-

-

-

-

Cash paid for income taxes

38

45

17

11

335

329

0

17,157

2,042

27

45

Cash paid for interest

0

1,031

2,692

3,300

3,300

3,227

1,200

495

14

17

28

Noncash investing activities:
Financed portion of leasehold improvements

-

-

-

-

-

-

-

-

-

451

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

37

259

-

Common stock issued for Talon acquisition

-

-

-

-

-

-

-

-

-

259

-